| Valuation of EuroQol five-dimensional questionnaire, youth version (EQ-5D-Y) and EuroQol five-dimensional questionnaire, three-level version (EQ-5D-3L) health states: the … S Kreimeier, M Oppe, JM Ramos-Goñi, A Cole, N Devlin, M Herdman, ... Value in Health 21 (11), 1291-1298, 2018 | 82 | 2018 |
| Headroom approach to device development: current and future directions A Girling, R Lilford, A Cole, T Young International journal of technology assessment in health care 31 (5), 331-338, 2015 | 54 | 2015 |
| The debate on indication-based pricing in the US and five major European countries A Towse, A Cole, B Zamora OHE Consulting Report. London: Office of Health Economics, 2018 | 26 | 2018 |
| Are the UK systems of innovation and evaluation of medical devices compatible? The role of NICE’s Medical Technologies Evaluation Programme (MTEP) AM Chapman, CA Taylor, AJ Girling Applied health economics and health policy 12, 347-357, 2014 | 25 | 2014 |
| A review of NICE methods and processes across health technology assessment programmes: why the differences and what is the impact? E Cowles, G Marsden, A Cole, N Devlin Applied health economics and health policy 15, 469-477, 2017 | 23 | 2017 |
| Early HTA to inform medical device development decisions-the headroom method AM Chapman, CA Taylor, AJ Girling XIII Mediterranean Conference on Medical and Biological Engineering and …, 2014 | 23 | 2014 |
| Sources and characteristics of utility weights for economic evaluation of pediatric vaccines: a systematic review M Herdman, A Cole, CK Hoyle, V Coles, S Carroll, N Devlin Value in Health 19 (2), 255-266, 2016 | 21 | 2016 |
| A review of NICE Methods across health technology assessment programmes: differences, justifications and implications E Brockis, G Marsden, A Cole, N Devlin London, The Office of Health Economics (OHE), 2016 | 18 | 2016 |
| Outcome-based payment schemes: what outcomes do patients with cancer value? P Lorgelly, J Pollard, P Cubi-Molla, A Cole, D Sim, J Sussex The Patient-Patient-Centered Outcomes Research 13, 599-610, 2020 | 15 | 2020 |
| Making outcome-based payment a reality in the NHS A Cole, P Cubi-Molla, J Pollard, D Sim, R Sullivan, J Sussex, P Lorgelly Office of Health Economics Research Papers, 2019 | 14 | 2019 |
| Economics of innovative payment models compared with single pricing of pharmaceuticals A Cole, A Towse, P Lorgelly, R Sullivan London: Office of Health Economics, 2018 | 14 | 2018 |
| A framework to manage the early value proposition of emerging healthcare technologies SM Davey, M Brennan, BJ Meenan, R McAdam, A Girling, A Chapman, ... Irish Journal of Management 31 (1), 59-75, 2011 | 13 | 2011 |
| Valuing EQ-5D-5L health states ‘in context’using a discrete choice experiment A Cole, K Shah, B Mulhern, Y Feng, N Devlin The European Journal of Health Economics 19, 595-605, 2018 | 12 | 2018 |
| Digital cognitive behavioural therapy for insomnia and primary care costs in England: an interrupted time series analysis C Sampson, E Bell, A Cole, CB Miller, T Marriott, M Williams, J Rose BJGP open 6 (2), 2022 | 11 | 2022 |
| Barriers to uptake of minimal access surgery in the united kingdom A Cole, P O’Neill, C Sampson, P Lorgelly OHE Consulting Report, London: Office of Health Economics, 2018 | 10 | 2018 |
| Legal barriers to the better use of health data to deliver pharmaceutical innovation A Cole, A Towse London: Office of Health Economics, 2018 | 9 | 2018 |
| Data governance arrangements for real-world evidence A Cole, L Garrison, J Mestre-Ferrandiz, A Towse London, UK: Office of Health Economics, 2015 | 8 | 2015 |
| Payment Models for Multi-Indication Therapies A Cole, M Neri, G Cookson Online.(Accessed July 2022), 2023 | 7 | 2023 |
| Indication-Based pricing (IBP) discussion paper A Cole, A Towse, B Zamora Office of Health Economics: London, UK, 2019 | 7 | 2019 |
| A review of NICE methods across health technology assessment programmes: differences, justifications and implications. Office of Health Economics. April 2016 E Brockis, G Marsden, A Cole, N Devlin | 7 | 2019 |
